Traws Pharma, Inc. Net Income (Loss) Available to Common Stockholders, Diluted
Traws Pharma, Inc. (TRAW) reported Net Income (Loss) Available to Common Stockholders, Diluted of -$2.61 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-14.
Financial Statements › Income Statement › Net Income
us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted · last filed 2026-08-14
- Traws Pharma, Inc. net income (loss) available to common stockholders, diluted for the quarter ending 2026-06-30 was -$2.61M.
- Traws Pharma, Inc. net income (loss) available to common stockholders, diluted for the quarter ending 2026-03-31 was -$5.69M, a 137.74% decline year-over-year.
- Traws Pharma, Inc. net income (loss) available to common stockholders, diluted for the quarter ending 2025-12-31 was -$5.40M.
- Traws Pharma, Inc. net income (loss) available to common stockholders, diluted for the quarter ending 2025-09-30 was -$3.04M.
- Traws Pharma, Inc. net income (loss) available to common stockholders, diluted for fiscal 2025 was $6.87M.
- Traws Pharma, Inc. net income (loss) available to common stockholders, diluted for fiscal 2024 was -$54.67M.
- Traws Pharma, Inc. net income (loss) available to common stockholders, diluted for fiscal 2023 was -$18.95M.
| Period end | Net Income (Loss) Available to Common Stockholders, Diluted 3 month | Net Income (Loss) Available to Common Stockholders, Diluted 6 month | Net Income (Loss) Available to Common Stockholders, Diluted 9 month | Net Income (Loss) Available to Common Stockholders, Diluted 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$2.61M 10-Q · filed 2026-08-14 | -$8.45M 10-Q · filed 2026-08-14 | -$13.70M derived: sum of 3 quarters · filed 2026-08-14 | -$16.74M derived: sum of 4 quarters · filed 2026-08-14 |
| 2026-03-31 | -$5.69M 10-Q · filed 2026-05-15 | -$11.09M derived: sum of 2 quarters · filed 2026-05-15 | -$14.13M derived: sum of 3 quarters · filed 2026-05-15 | -$14.75M derived: sum of 4 quarters · filed 2026-08-14 |
| 2025-12-31 | -$5.40M derived: 10-K 12 month − 10-Q 9 month · filed 2026-04-15 | -$8.43M derived: sum of 2 quarters · filed 2026-04-15 | -$9.06M derived: sum of 3 quarters · filed 2026-08-14 | $6.87M 10-K · filed 2026-04-15 |
| 2025-09-30 | -$3.04M 10-Q · filed 2025-11-13 | -$3.66M derived: sum of 2 quarters · filed 2026-08-14 | $12.26M 10-Q · filed 2025-11-13 | -$10.00M derived: sum of 4 quarters · filed 2026-08-14 |
| 2025-06-30 | -$625.00K 10-Q · filed 2026-08-14 | $14.86M 10-Q · filed 2026-08-14 | -$6.96M derived: sum of 3 quarters · filed 2026-08-14 | -$8.39M derived: sum of 4 quarters · filed 2026-08-14 |
| 2025-03-31 | $15.08M 10-Q · filed 2026-05-15 | -$6.34M derived: sum of 2 quarters · filed 2026-05-15 | -$7.77M derived: sum of 3 quarters · filed 2026-05-15 | -$28.54M derived: sum of 4 quarters · filed 2026-05-15 |
| 2024-12-31 | -$21.42M derived: 10-K 12 month − 10-Q 9 month · filed 2026-04-15 | -$22.85M derived: sum of 2 quarters · filed 2026-04-15 | -$43.63M derived: sum of 3 quarters · filed 2026-04-15 | -$54.67M 10-K · filed 2026-04-15 |
| 2024-09-30 | -$1.43M 10-Q · filed 2025-11-13 | -$22.21M derived: sum of 2 quarters · filed 2025-11-13 | -$33.26M 10-Q · filed 2025-11-13 | |
| 2024-06-30 | -$20.77M 10-Q · filed 2025-08-14 | -$34.72M 10-Q · filed 2025-08-14 | ||
| 2024-03-31 | -$4.98M 10-Q · filed 2025-05-15 | |||
| 2023-12-31 | -$18.95M 10-K · filed 2025-03-31 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Alzamend Neuro, Inc. (ALZN) | United States | $0.009B | |
| Imunon, Inc. (IMNN) | United States | $0.008B | -0.56 |
| SOLIGENIX, INC. (SNGX) | United States | $0.008B | |
| FibroBiologics, Inc. (FBLG) | United States | $0.009B | -0.27 |
| EXICURE, INC. (XCUR) | United States | $0.008B | -1.54 |
| Ensysce Biosciences, Inc. (ENSC) | United States | $0.008B | -0.37 |
| InMed Pharmaceuticals Inc. (INM) | $0.008B | -0.65 | |
| Aprea Therapeutics, Inc. (APRE) | United States | $0.010B | -0.78 |
| Apimeds Pharmaceuticals US, Inc. (APUS) | United States | $0.008B | |
| CNS Pharmaceuticals, Inc. (CNSP) | United States | $0.007B |